FDA Approvals Remain Unfazed by Vioxx Recall

Strategic Insights -

Recent votes by federal advisers indicate that safety concerns won't slow down approval of new therapies, contradicting expectations that the Food and Drug Administration would become more cautious following the Vioxx recall. Despite fears that the agency would put the brakes on new drug approvals, the FDA's advisory panels have recommended the approval of several cancer drugs, including those from Merck & Co. and Sanofi-Synthelabo. These moves suggest that the agency's focus remains on balancing speed with safety.

Key Takeaways:

  • The FDA's advisory panels have recommended the approval of three out of four cancer drugs up for consideration, including those from Merck & Co. and Sanofi-Synthelabo.
  • The agency's decision to pull the painkiller Vioxx did not lead to a significant slowdown in the approval process, contradicting expectations from industry experts.
  • Cancer drugs, which generated $11.2 billion in revenue in 2004, have the most revenue potential in the pharmaceutical market, with 400 products in the pipeline.
  • The FDA has devised ways to speed its drug review process, including delaying the receipt of key facts in exchange for getting life-saving products to patients faster.
  • Scott Gottlieb, FDA deputy commissioner for medical and scientific affairs, stated that the agency's panels shift subtly in response to science, not dramatically due to the fall of a blockbuster drug like Vioxx.
  • Former FDA chief counsel Peter Barton Hutt noted that the agency has become more conservative in its approval process since 1999, requiring longer, more complex clinical trials and more dosage levels.
  • Dr. Silvana Martino, chairwoman of the panel in Maryland, emphasized the need for caution in the approval process, stating that the goal is to find new drugs that really work for the 1.4 million Americans diagnosed with cancer each year.

Statistics:

  • $11.2 billion: The revenue generated by cancer drugs in 2004.
  • 400: The number of products in the pipeline for cancer drugs.
  • 1.4 million: The number of Americans diagnosed with cancer each year.
  • 1999: The year when the FDA began to toughen its approval process, requiring longer, more complex clinical trials and more dosage levels.

Sources:

  • The Boston Globe
  • Merck & Co.
  • Sanofi-Synthelabo
  • Keck School of Medicine
  • Peter Barton Hutt, former FDA chief counsel
  • Scott Gottlieb, FDA deputy commissioner for medical and scientific affairs
  • Dr. Silvana Martino, chairwoman of the panel in Maryland
  • Derek Taller, senior biotechnology analyst for Cathay Financial Inc.